Inhaling asbestos fibres causes cancer (both mesothelioma and lung cancer). These are related to the amount of asbestos inhaled. This study will look at lung tissue removed from people for other medical reasons to see if those at high risk (e.g. construction workers) have benefited from the laws restricting asbestos use. We hope to predict rates of these cancers in the future from these results, based on the numbers of fibres seen in the lungs.
Novel Surgery-chemotherapy-immunotherapy Approaches For Lung Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$662,819.00
Summary
Many patients undergo cancer surgery every year yet still die of cancer over the next few years because the surgeon couldnt remove all of the cancer cells, many of which were undetectable at the time of surgery. This grant will develop ways of combining chemotherapy drugs with immune therapy to 'mop up' hidden residual cancer cells after operations - the immune system, when stimulated appropriately, should be able to 'seek and destroy' those hidden deposits and thus cure these cancers.
Improving Treatment Outcomes For Malignant Mesothelioma Patients Using Biomarkers.
Funder
National Health and Medical Research Council
Funding Amount
$795,262.00
Summary
The deadly asbestos-induced cancer mesothelioma is continuing to kill tens of thousands of people each year. Most patients are diagnosed with advanced disease. In this study we will use novel biomarkers to help the diagnosis of mesothelioma and potentially improve treatment options for patients.
Compartmental Analysis Of T-cell Responses In Thoracic Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$851,403.00
Summary
To improve immune therapy for cancer we have to be able to determine how cancer patients ‘see’ mutated cancer proteins. Blood is the easiest & most useful source of immune ‘killer’ cells for that task, but the lymph node that drains the tumour and the fluid that bathes a tumour probably contain a much higher number of these killer cells than blood. If so, studying them would help us better track responses to therapy and enable us to choose the best mutated proteins for a vaccine.
Reactivities Of CD8 T Cells To Mutated Neo-antigens In Lung Malignancies
Funder
National Health and Medical Research Council
Funding Amount
$661,979.00
Summary
Tumours express mutated proteins (called ‘neo-antigens’) which can be targets of powerful killer T cells which can destroy cancer cells. To understand why these cells fail to cure most cancers we will study neo-antigens identified by modern DNA sequencing methods to identify these neo-antigens & the responses to them. Then it will be possible to design trials in individual patients, e.g. personalised vaccines to ‘force’ the immune system to attack cells bearing these neo-antigens.
Therapeutic Targeting Of A New Growth Factor In Mesothelioma
Funder
National Health and Medical Research Council
Funding Amount
$317,775.00
Summary
Malignant mesothelioma is an aggressive and incurable cancer. This study will build on our recent data showing a protein termed FGF-9, not previously linked with mesothelioma, could significantly stimulate mesothelioma growth. This project will examine the biologic activities of FGF-9 and its receptors in mesothelioma, and the therapeutic benefits of antagonizing FGF-9 in mesothelioma in vivo.
Cancers have thousands of mutations, so they should look a bit like a viral infection. If so, why doesn’t the immune system just destroy them outright, like they would a virus? We think the mutated proteins cause a ‘brake’ to be put on the anti-cancer immune response, and also that cancers subvert the anti-cancer attack by remaining hidden in the target zone. Unblocking these “brakes” might lead to new treatments.
This project will update the Wittenoom cohorts by tracing cancers and deaths in Australia and Italy. This will improve risk estimates of lung cancer and mesothelioma. In particular we will see if that risk declines with more than 40 years since exposure, in collaboration with Italian colleagues. We will continue developing an interactive community website to act as a support platform, a layman's bridge to medical research knowledge, public health information and an archive of personal stories.